Genetics of Coxiella burnetii

伯内氏柯克斯体的遗传学

• 批准号: 7592301
• 负责人: robert a heinzen
• 金额: $ 83.28万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7592301
• 关键词: Accounting; Acute; Antibiotics; Antigens; Architecture; Attenuated; Bacteria; Biogenesis; Bioinformatics; Biology; Buffers; Categories; Cells; Centers for Disease Control and Prevention (U.S.); Chimeric Proteins; Chronic; Chronic Disease; Cloning; Collection; Condition; Coxiella; Coxiella burnetii; DNA; Development; Diagnostic; Dose; Endocarditis; Enzyme-Linked Immunosorbent Assay; Excision; Fever; Formates; Future; Gene Expression Regulation; Genes; Genetic; Genetic Polymorphism; Genetic Transcription; Genetic Transformation; Genetic Variation; Genome; Genomics; Human; Immune Sera; In Vitro; Individual; Infection; Influenza; Investigation; Length; Lesion; Lipopolysaccharides; Metabolic; Methods; Microarray Analysis; Micromanipulation; Modeling; Molecular Biology; Molecular Weight; Mus; Nature; Numbers; Organism; Organism Cloning; Other Genetics; Pathogenesis; Phagolysosome; Phase; Phenotype; Procedures; Production; Protein Microchips; Proteins; Proteome; Proteomics; Q Fever; RNA; Reproduction spores; Resistance; Screening procedure; Source; Specificity; Stimulus; Stress; Structure; Subunit Vaccines; System; Techniques; Testing; Translations; Vaccination; Vaccines; Vacuole; Variant; Virulence; Virulence Factors; Virulent; Whole Organism; Zoonoses; base; biothreat; comparative; egg; extracellular; factor C; fitness; genetic manipulation; genome sequencing; high throughput screening; immunogenic; improved; in vivo; insight; killings; monolayer; mutant; novel vaccines; pathogen; response; tissue culture; tool; vaccine efficacy

We have made significant progress in acquiring C. burnetii RNA from infected cells that is suitable for microarray analysis. In conjunction with our system to synchronously infect cells with the environmentally stable SCV, we can now investigate the coordinated gene regulation occurring during C. burnetii morphological development. Moreover, we have formulated a buffer that dramatically improves extracellular C. burnetii metabolic fitness. This will allow investigation of C. burnetii transcriptional responses to diverse environmental stimuli under defined conditions. We have finished sequencing the genomes of the K and G human endocarditis isolates and the attenuated Dugway isolate. Extensive bioinformatic analysis is ongoing to define Coxiella pathogenetic determinants, evolutionary relationships, and mechanisms of genome plasticity. As part of our ongoing efforts to develop genetic systems for C. burnetii, we have developed a new method to clone the organism that involves excision of individual C. burnetii-laden vacuoles from infected cell monolayers by micromanipulation. This is an efficient and reproducible procedure to obtain C. burnetii clones, and utilization of this technique will dramatically aid our ability to clone and analyze isogenic mutants of the organism. Lipopolysaccharide is the only defined virulence factor of C. burnetii. Virulent phase I organisms, producing full-length LPS, convert to avirulent phase II organisms, synthesizing severely truncated LPS, upon repeat in vitro passages. Using the cloning procedure descried about, we have cloned and are now expanding a number of phase II clones of different isolates of Coxiella. Expansion of these clones will allow SNP analysis via re-sequencing microarrays to define SNPs and other genetic polymorphisms associated with conversion to phase II and avirulence. Using proteins generated by in vitro transcription and translation, we have constructed a protein microarray that contains approximately 1500 Coxiella proteins (75% of the Coxiella proteome). By probing this array with a collection of human immune serum, we have identified roughly 50 immunogenic proteins. Fusion proteins corresponding to the 10 most highly immunogenic proteins have been purified and these are currently being tested in an ELISA formate for there utility as a Q fever diagnostic. Future plans include testing these proteins for vaccine efficacy in a murine model of Q fever.

我们在从感染细胞中获取适合微阵列分析的伯纳氏梭菌RNA方面取得了重大进展。结合我们的系统与环境稳定的SCV同步感染细胞，我们现在可以研究伯氏梭菌形态发育过程中发生的协调基因调控。此外，我们已经制定了一种缓冲液，显着提高胞外C. burnetii代谢适应性。这将允许在确定的条件下调查伯氏梭菌对不同环境刺激的转录反应。